Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
<h4>Background</h4>Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 diabetes often excluded from clinical trials on this association, is poorly understood. Thus, we...
Main Authors: | Sheriza N Baksh, Jodi B Segal, Mara McAdams-DeMarco, Rita R Kalyani, G Caleb Alexander, Stephan Ehrhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0240141 |
Similar Items
-
Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
by: Sheriza Baksh, et al.
Published: (2021-08-01) -
Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021-09-01) -
A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01) -
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
by: Tzu-Lan Huang, et al.
Published: (2019-01-01) -
Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
by: Marile Santamarina, et al.
Published: (2019-03-01)